HC Wainwright reiterated their buy rating on shares of I-Mab (NASDAQ:IMAB - Free Report) in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a $7.00 target price on the stock.
Separately, Needham & Company LLC upped their price target on I-Mab from $4.00 to $5.00 and gave the stock a "buy" rating in a research note on Friday, June 27th.
Get Our Latest Research Report on I-Mab
I-Mab Stock Performance
Shares of IMAB traded down $0.26 during trading hours on Wednesday, hitting $2.05. 392,373 shares of the company were exchanged, compared to its average volume of 395,220. The firm's 50 day moving average is $1.75 and its 200-day moving average is $1.20. I-Mab has a 52 week low of $0.60 and a 52 week high of $3.08.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the company. HBK Sorce Advisory LLC acquired a new position in I-Mab in the 1st quarter valued at $38,000. Ground Swell Capital LLC acquired a new position in I-Mab in the 1st quarter valued at $53,000. Millennium Management LLC grew its stake in I-Mab by 763.1% in the 4th quarter. Millennium Management LLC now owns 97,749 shares of the company's stock valued at $83,000 after buying an additional 86,424 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in I-Mab in the 4th quarter valued at $93,000. Finally, Cantor Fitzgerald L. P. acquired a new position in I-Mab in the 4th quarter valued at $119,000. 38.38% of the stock is currently owned by institutional investors and hedge funds.
About I-Mab
(
Get Free Report)
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.
Featured Stories
Before you consider I-Mab, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and I-Mab wasn't on the list.
While I-Mab currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.